Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

Roche Holding, the Swiss pharmaceutical giant, said on Thursday that its group sales rose by 7% in the first quarter to 14.4 ...

Roche posted higher sales that beat analysts’ expectations on higher demand for its key drugs.

Roche (RHHBY) expects an increase in Group sales in the mid single digit range at CER. Core earnings per share are targeted to develop in the ...

(Reuters) -Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the ...

Group sales grew by 6% at constant exchange rates; 7% in CHF, driven by high demand for newer medicines and diagnostic solutions. Roche (RHHBY) ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 ...

In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical ...

Executive Vice-President and Chief Marketing Officer John Brooks will address the 2025 Bank of America Industrials, ...

Swiss drugmaker Roche said on Thursday its first-quarter sales rose 7% to 15.44 billion Swiss francs ($18.64 billion) and it ...